Guyuan Medical Files IPO Prospectus: A Full-Stack Solution Provider in Medical Polymer Products with Two Decades of Expertise

A Manufacturing Powerhouse, Materials First. New materials are a critical foundation supporting the nation’s strategic emerging industries and serve as the industrial cornerstone for the transformation and upgrading of the entire manufacturing sector. In the medical field, every breakthrough in medical materials has driven significant industry transformations, spurring the development of new medical devices and revitalizing traditional ones.

As domestically produced medical devices steadily achieve import substitution in the low- and mid-end markets and continue to make inroads into the high-end segment, the strategic value of upstream enterprises in the medical device industry chain has become increasingly prominent.

In August 2024, Shenzhen GuYuan Plastic Produce Co., Ltd. (hereinafter referred to as “GuYuan Medical”), a comprehensive solutions provider for medical polymer products, announced the completion of its tens-of-millions-yuan Series A financing round invested by Guiyang Venture Capital. This marks another recognition and endorsement from the capital market for GuYuan Medical within just six months.

Since its establishment, GuYuan Medical has been deeply engaged in the field of medical polymer materials and products for nearly two decades. To date, it has accumulated significant technical advantages in precision mold design and manufacturing, production processes for core components of medical consumables and equipment, and formulations of medical polymer materials. Its products are widely used in scenarios such as in vitro diagnostics, gene sequencing, and life support.GuYuan Medical has also become a long-term, high-quality supplier to leading healthcare enterprises such as Mindray Medical, Snibe Diagnostics, YHLO Biotech, and MGI Tech.

GuYuan Medical’s origins can be traced back to 1997, when it began with precision mold injection molding technology, accumulating substantial expertise in manufacturing processes and production resources.

2005, GuYuan Medical was officially established. After nearly two decades of dedicated cultivation, the company has become a leading domestic provider of medical polymer product solutions.

To deepen its industrial chain layout, GuYuan Medical has established a dedicated Medical New Materials Division, led by senior experts from the Department of Polymer Materials at Sichuan University. Within just eight months of its establishment, the team achieved a “zero-to-one” breakthrough for GuYuan Medical in upstream medical materials. Their independently developed material formulations have helped clients overcome production bottlenecks and reduce material costs in the field of high-pressure contrast injectors, successfully replacing previous import suppliers.

To continuously stimulate innovation, GuYuan Medical has engaged in deep collaboration with authoritative experts from top-tier institutions such as Sichuan University and Sun Yat-sen University. By strengthening the industry-academia-research cooperation model and increasing investment in the R&D of upstream medical materials and the horizontal expansion of its product lines, GuYuan Medical empowers partners across the healthcare industry.

GuYuan Medical’s new materials team has demonstrated strong initiative, achieving significant progress in high-value consumables such as contrast catheters and microfluidics. Its independently developed new material products have garnered high recognition from customers, demonstrating the feasibility of domestic substitution for high-end medical-grade polymer materials through technical solutions. The company’s product portfolio is also increasingly diverse, covering a range of in vitro diagnostics and biological laboratory supplies, including chemiluminescent immunoassay kits, gene sequencing products, and blood collection tubes.

GuYuan Medical IVD Laboratory Consumables, image from the company’s official website

Guided by customer needs, GuYuan Medical has established polymer materials and engineering as its core strategic focus, concentrating on niche segments of the medical device industry such as in vitro diagnostics (IVD), gene sequencing, and life sciences. Its multiple core products, including chemiluminescence immunoassay kits, COP reaction cups, and gene sequencing cartridges, all feature industry-leading manufacturing processes that integrate innovative advancements in polymer processing technology, demonstrating the company’s technical prowess.

Leveraging its robust team, GuYuan Medical can engage deeply at the early stages of customer product development to accurately grasp client needs. In the face of challenges, the team responds swiftly, placing particular emphasis on pre-sales services by collaborating closely with clients and providing customized recommendations based on extensive experience.

Throughout the material product development process, GuYuan has accumulated extensive “know-how.” For instance, designs that appear largely similar may yield different performance outcomes during testing; such variations are all traceable to a thorough understanding and stringent control of key process parameters. Leveraging over two decades of industry expertise, GuYuan has effectively addressed a wide range of challenges for more than one hundred clients across China’s medical sector, ensuring every response is both rapid and precise.

In response to the dynamic and ever-changing market demands, GuYuan Medical flexibly adjusts its strategies to provide small-batch, personalized, and agile customization services for innovative medical device manufacturers. By offering comprehensive solutions covering every stage—from material selection and processing characteristics to post-processing—GuYuan Medical not only shortens clients’ R&D cycles and reduces production costs but also lowers the societal costs associated with redundant research and development. For clients with only preliminary concepts, GuYuan Medical also provides end-to-end solutions spanning from concept realization to mass production.

Of particular note, Guyuan Medical’s core competitiveness lies in its more than two decades of deep expertise in medical products, having built an end-to-end solution that spans precision mold design and manufacturing, R&D of medical-grade polymer materials, and lean production of medical consumables and structural components for medical devices. Currently, Guyuan Medical has largely achieved fully automated “lights-out” manufacturing, which not only enhances production efficiency but also ensures a high degree of product consistency.

Mold Intelligent Manufacturing Center, image from the company's official website

Kong Chuigui, head of the medical consumables division at GuYuan Medical, told VCBeat that one of the primary challenges in the mass production of new medical polymer materials is ensuring a clean production environment. Traditional non-clean workshops struggle to prevent the intrusion of dust and impurities; these particles can permeate raw materials and products during the manufacturing process, thereby affecting the stability of clients’ reagent filling operations and potentially leading to deviations such as false-positive test results. Achieving full-chain cleanliness—from raw materials and production to packaging and transportation—undoubtedly requires substantial financial and technical support. Despite the prevailing uncertainties in the current environment, GuYuan Medical has continued to invest counter-cyclically in new production bases and cleanrooms to ensure the stability of medical product manufacturing.

GuYuan Medical’s portfolio spans immunology, clinical chemistry, molecular diagnostics, POCT, and microbiology, covering a vast horizontal and vertical scope. In addition, the company must continuously address emerging market demands. How does GuYuan manage such an extensive and deep-reaching “front line”?

GuYuan Medical has adopted a “dichotomy” strategy. First, it established independent business units based on major product categories, such as the Medical Equipment Division and the Medical Consumables Division, to achieve specialized management. Furthermore, within each division, product subcategories are further refined; for instance, the Medical Consumables Division has set up a dedicated production line for reaction cups, with fixed professional teams responsible for manufacturing similar or related products. This approach ensures continuous improvement in team expertise and sustained optimization of product quality. For the research, development, and introduction of new products, GuYuan Medical strategically groups together those with similar technologies or shared manufacturing processes. Through accumulated experience and knowledge over time, the company has gradually built an insurmountable competitive advantage.

Leveraging its in-house capabilities in mold and consumable product R&D and design, along with state-of-the-art injection molding processes, GuYuan Medical not only provides end-to-end R&D, production, and manufacturing of material-based products for clients but also offers advanced OEM product design solutions to downstream customers, facilitating the development and production of customized products.

To date, GuYuan has served nearly 200 enterprises and established long-term, stable partnerships with leading manufacturers such as Mindray, Snibe, YHLO, and MGI Tech. In 2023, GuYuan Medical became one of the few companies in the industry to achieve counter-trend revenue growth.

Some of GuYuan Medical’s partners. Image provided by the company.

Thanks to its collaborations with numerous leading manufacturers, GuYuan Medical’s brand strength continues to rise, while its production system is being continuously refined and perfected within the mature supply chains of global industry leaders.Notably, the collaboration with Mindray has continued from 1999 to the present.

At the end of 2023, GuYuan Medical announced its brand internationalization and globalization strategy. In 2024, GuYuan Medical officially embarked on its overseas expansion, successively entering markets in Southeast Asia, Africa, South America, and other regions, collaborating withUK anesthesia breathing equipment manufacturer Penlon, Indian medical device giant Meril Life Sciencesto establish a partnership and jointly explore the global market.

Faced with a dazzling array of consumables suppliers, how can downstream customers select the partner that best fits their needs? Kong Chuigui offers two recommendations.First, assess whether upstream consumables manufacturers have prior experience in producing similar products, with particular emphasis on evaluating their mass production and delivery capabilities.. Merely achieving development capability is only the first step; the key lies in possessing the capacity for stable, large-scale manufacturing, production, and delivery;Second, assess the team’s emphasis on technology., whether the team can fully master the product, whether cost and quality are optimized, and whether delivery timelines can meet customer demands—all of these are underpinned by technical capabilities.

Taking mold development as an example, the first step is to assess whether the supplier can meet the basic requirements for mold making, such as “1-out-of-64” or “1-out-of-96” cavities (i.e., producing 64 or 96 identical parts per injection molding cycle). The second consideration is whether the manufacturer can provide additional optimization recommendations. Many suppliers may be capable of completing basic mold-making tasks, but the preferred partners—those who truly “master” the product, have accumulated extensive experience, and can deliver efficient services—are those who deeply understand the product’s technical logic, anticipate and resolve potential issues, and even proactively propose optimization solutions ahead of customer requests.

Regarding the differences between domestic and international markets, Kong Chuigui pointed out that while product demand is quite similar in both, the customer profiles differ significantly. In China, companies are highly price-sensitive due to factors such as the centralized procurement policy. In contrast, in international markets, quality is the primary consideration, with price being relatively secondary. Additionally, there are differences in service models: domestic clients often require early intervention from GuYuan and OEM services, whereas international clients have clear product requirements and efficient communication, typically collaborating directly based on explicit technical specifications. The primary medium of communication for both parties is essentially “a single drawing.”

In the face of uncertainties in import and export trade policies and the challenges they pose to supply chain stability, Kong Chuigui stated that GuYuan Medical is actively responding by accelerating collaborative efforts with customers in material research and development to enhance its independent innovation capabilities. Meanwhile, for critical “chokepoint” materials, the company has adopted a strategic reserve strategy to ensure the resilience and sustainability of its supply chain.

In 2024, GuYuan Medical entered a new phase of vigorously promoting integrated solutions for medical polymer products. The company will concentrate its advantageous resources in the field of in vitro diagnostics, tailoring high-quality material products to meet the specific needs of diverse customers.Empowering customers comprehensively with an integrated solution encompassing “material formulation + mold design + injection molding production.”Meanwhile, the Company will continue to actively expand into new overseas markets, bringing high-quality products and services to the global stage, and ushering in a new chapter in the internationalization of the GuYuan Medical brand.